Company Overview and News

 
Visdynamics' external auditors resign

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): Visdynamics Holdings Bhd's external auditors Messrs Adam & Co have resigned from their position effective Oct 4.
BSMAF 0120 1818

 
Stock With Momentum: VisDynamics Holdings

2018-10-05 theedgemarkets
VisDynamics Holdings Bhd (-ve) TRADING of shares in VisDynamics Holdings Bhd (fundamental: 2.6/3, valuation: 0.8/3) triggered our momentum algorithm yesterday for the seventh time this year. The stock slid two sen or 2.6% to close at 75 sen.
0120

 
Stock With Momentum: VisDynamics Holdings

2018-09-26 theedgemarkets
VisDynamics Holdings Bhd (+ve) Trading of shares in VisDynamics Holdings Bhd (fundamental: 2.6/3, valuation: 1.2/3) slipped 0.5 sen or 0.71% to settle at 70 sen yesterday, after 4.89 million shares crossed.
0120

 
KLCI gets off to muted start, stays firmly above 1,800-level

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI got off to a muted start this morning but stayed firmly above the crucial 1,800-point level.
UPBMF 7113 TPGVF BATS 4162 2089 6033 0120 TGLVY PNADF 6888 AXXTF 1902 PNAGF

 
Stock With Momentum: VisDynamics Holdings

2018-07-05 theedgemarkets
SHARES in VisDynamics Holdings Bhd (fundamental: 2.6/3, valuation: 0.6/3) has triggered our proprietary momentum algorithm yesterday. The counter closed 7.5 sen or 15.96% higher at 54.5 sen with some 9.7 million shares traded, exceeding its 200-day average volume of 817,798 shares.
0120

 
KLCI pares gains in line with shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719

 
Stock With Momentum: VisDynamics Holdings

2018-06-21 theedgemarkets
VisDynamics Holdings Bhd (-ve) SHARES in VisDynamics Holdings Bhd (fundamental: 2.6/3, valuation: 1.2/3), which triggered our momentum algorithm for the first time since January this year, pushed the stock’s price up three sen or 6.32% higher to 50.5 sen apiece.
0120

 
Visdynamics jumps 7.37% on positive technicals

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): Visdynamics Holdings Bhd rose 7.37% at mid-morning today, following a positive technical outlook on the stock.
0120

 
Visdynamics may climb higher, says RHB Retail Research

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): RHB Retail Research said Visdynamics Holdings Bhd may climb higher after forming a white candle and hitting its highest close in more than two months.
0120

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...